1194 related articles for article (PubMed ID: 17292895)
1. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
2. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
[TBL] [Abstract][Full Text] [Related]
3. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study.
Ferrari B; Barusi L; Coppola F
J Reprod Med; 2002 Feb; 47(2):137-43. PubMed ID: 11883353
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
5. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
6. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
[TBL] [Abstract][Full Text] [Related]
7. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
[TBL] [Abstract][Full Text] [Related]
8. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization.
Kovacs P; Kovats T; Kaali SG
Fertil Steril; 2010 Feb; 93(2):475-9. PubMed ID: 19200991
[TBL] [Abstract][Full Text] [Related]
9. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization.
Lisi F; Rinaldi L; Fishel S; Caserta D; Lisi R; Campbell A
Fertil Steril; 2005 Feb; 83(2):309-15. PubMed ID: 15705367
[TBL] [Abstract][Full Text] [Related]
11. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
[TBL] [Abstract][Full Text] [Related]
12. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
[TBL] [Abstract][Full Text] [Related]
13. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
14. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?
Berkkanoglu M; Ozgur K
Fertil Steril; 2010 Jul; 94(2):662-5. PubMed ID: 19368912
[TBL] [Abstract][Full Text] [Related]
15. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
16. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
19. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques.
Ferraretti AP; Gianaroli L; Magli MC; D'angelo A; Farfalli V; Montanaro N
Fertil Steril; 2004 Dec; 82(6):1521-6. PubMed ID: 15589853
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
